已收盘 02-06 16:00:00 美东时间
+0.810
+4.32%
今日重点评级关注:HC Wainwright & Co.:维持NioCorp Developments"买入"评级,目标价从9.5美元升至11.25美元;摩根士丹利:维持Chewy"超配"评级,目标价从48美元升至51美元
01-14 11:25
今日重点评级关注:Needham:维持Vaxcyte"买入"评级,目标价从90美元升至110美元;Citizens: 维持LGI Homes"跑赢大市"评级,目标价从85美元升至95美元
01-08 18:33
JP Morgan analyst Pablo Singzon maintains Baldwin Insurance (NASDAQ:BWIN) with a Neutral and lowers the price target from $33 to $28.
01-07 23:44
今日重点评级关注:杰富瑞:维持ImmunityBio Inc Ordinary Shares"买入"评级,目标价从8美元升至9美元;B. Riley证券:维持WAVE Life Sciences"买入"评级,目标价从19美元升至37美元
2025-12-15 15:30
Wells Fargo analyst Elyse Greenspan upgrades Baldwin Insurance (NASDAQ:BWIN) from Underweight to Equal-Weight and maintains the price target from $25 to $25.
2025-12-13 00:33
今日重点评级关注:Stifel:维持X4 Pharmaceuticals"买入"评级,目标价从7.5美元升至10美元;花旗:维持UP Fintech Holding"买入"评级,目标价从17.4美元升至17.5美元
2025-12-08 08:34
今日重点评级关注:摩根士丹利:维持Kyverna Therapeutics"超配"评级,目标价从20美元升至25美元;Maxim Group:维持Capricor Therapeutics"买入"评级,目标价从25美元升至50美元
2025-12-05 08:35
BMO Capital analyst Charlie Lederer maintains Baldwin Insurance (NASDAQ:BWIN) with a Market Perform and lowers the price target from $34 to $33.
2025-12-04 22:19
今日重点评级关注:Piper Sandler:维持MeiraGTx Hldgs"超配"评级,目标价从28美元升至30美元;RBC Capital:维持4D Molecular Therapeutics"跑赢大市"评级,目标价从26美元升至32美元
2025-11-12 11:43
今日重点评级关注:Guggenheim:维持InflaRx"买入"评级,目标价从10美元升至22美元;巴克莱:维持Tandem糖尿病护理"超配"评级,目标价从51美元升至55美元
2025-11-11 10:49